acitretin / Generic mfg. - LARVOL DELTA

Role of acitretin in regulating glucose and lipid homeostasis in an imiquimod-induced psoriasis model mouse. (PubMed, Zhong Nan Da Xue Xue Bao Yi Xue Ban) - "Acitretin helps maintain the balance between hepatic glycogenesis and gluconeogenesis, enhances insulin sensitivity, and improves pancreatic islet function, thereby promoting systemic and cellular glucose homeostasis."

Journal • Preclinical • Dermatology • Diabetes • Genetic Disorders • Immunology • Inflammation • Metabolic Disorders • Obesity • Psoriasis • AKT1 • PDX1 • PPARG • SIRT1 • SLC2A1 • SLC2A4

Identifying Key Genes and Approved Medications Associated with Major Depressive Disorder Using Network Analysis and Systems Biology. (PubMed, Iran J Psychiatry) - "These medications include Acitretin, Adalimumab, Alteplase, Cisplatin, Digoxin, Etanercept, Infliximab, Insulin, Omeprazole, Pentoxifylline, and Rabeprazole. This study provides a new vision of the pathogenesis and treatment of MDD. However, further experimental and clinical studies are necessary."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • IL1B • IL6 • STAT1 • STAT3

Successful management of recalcitrant cutaneous warts with low-dose acitretin monotherapy in a patient with idiopathic CD4+ lymphocytopenia. (PubMed, Skin Health Dis) - "As HPV evades the Janus kinase/STAT pathway to promote keratinocyte proliferation, acitretin may work through reversal of this mechanism. This case demonstrates effectiveness of acitretin in treating recalcitrant viral warts, specifically in a patient with ICL."

Journal • Monotherapy • Dermatology • Hematological Disorders • Human Papillomavirus Infection • Infectious Disease • Oncology • CD4 • STAT1

Psoriasis. (PubMed, Nat Rev Dis Primers) - "In moderate-to-severe disease, oral systemic therapies, such as methotrexate, ciclosporin, acitretin, apremilast and deucravacitinib, provide a range of immunomodulatory effects. Early screening for psoriatic arthritis, proactive cardiovascular risk reduction and multidisciplinary care are crucial to optimizing long-term outcomes. Ongoing research continues to advance precision medicine approaches, with the goal of enhancing treatment durability and improving quality of life for individuals living with psoriasis."

Journal • Review • Cardiovascular • CNS Disorders • Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Mental Retardation • Metabolic Disorders • Psoriasis • Psoriatic Arthritis • Psychiatry • Rheumatology • Seronegative Spondyloarthropathies • HLA-C • IL12A • IL12B • IL17A • IL17RA • IL23A • TYK2

Dramatic clearance of extensive psoriasis in a pediatric patient with upadacitinib (CDA 2025) - "Introduction : Psoriasis is a chronic inflammatory skin condition that commonly presents on the knees, elbows, trunk, and scalp, but can involve the palmoplantar surfaces. The patient presented with severe palmoplantar psoriasis at age 3, progressing to widespread disease by age 8, with genital involvement, painful fissures, and impaired mobility. He underwent extensive treatments, including methotrexate, acitretin, cyclosporine, ustekinumab, ixekizumab, apremilast, secukinumab, and deucravacitinib, alongside topical therapies including clobetasol, roflumilast, halobetasol and betamethasone diproprionate-based preparations. Despite moderate responses to some regimens, sustained control was not achieved, and treatment side effects, including elevated liver enzymes, dyslipidemia and gastrointestinal discomfort, further limited options."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Dyslipidemia • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Metabolic Disorders • Pain • Pediatrics • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Treatment of Refractory PRP with Off-label Guselkumab and Abrocitinib: A Promising Combination Therapy (CDA 2025) - "She had failed NBUVB phototherapy, cyclosporine, topical steroids and keratolytics, prednisone, and was currently taking acitretin alternating dose 25mg/35mg daily...She started combination of methotrexate and acitretin which failed. Ustekinumab 90mg every twelve weeks was initiated off-label with alitretinoin 30mg daily; no change...Current treatments approved for both psoriasis and atopic dermatitis seem to provide benefit, and combination therapy may be more beneficial. More research is necessary to find an effective single agent or to identify ideal doses of combination therapies."

Combination therapy • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology • Pruritus • Psoriasis • IL23A

Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Oral systemic therapies, including methotrexate, cyclosporine, acitretin, and apremilast, remain integral to psoriasis management, particularly for patients with moderate-to-severe disease who cannot afford biologic therapy. A balanced approach that integrates clinical monitoring, lifestyle modifications, and emerging precision medicine techniques is essential for optimizing long-term treatment outcomes. Future research should focus on refining predictive models for drug-induced liver injury and developing targeted therapies with improved efficacy and safety profiles."

Journal • Review • Dermatology • Hepatology • Immunology • Inflammation • Liver Failure • Psoriasis • TYK2

Investigating the efficacy of calcipotriol-acitretin combination therapy versus monotherapy protocols in psoriasis and its effect on serum inflammatory factors: a systematic review and meta-analysis. (PubMed, Eur J Med Res) - "The calcipotriol-acitretin combination therapy could be a safe and effective therapeutic strategy in the treatment of psoriasis. However, the lack of PROSPERO registration and the high heterogeneity in this study limited the conclusion, and more high-quality RCTs were needed for further evaluation."

Journal • Monotherapy • Retrospective data • Review • Dermatitis • Dermatology • Immunology • Inflammation • Pain • Psoriasis • IL10 • IL17A • IL23A • IL4 • IL6 • TNFA

Treatment of Hailey-Hailey disease with the Janus kinase inhibitor abrocitinib: A case report. (PubMed, SAGE Open Med Case Rep) - "Despite multiple failed therapies, including methotrexate, dapsone, acitretin, and naltrexone, she showed rapid improvement within 2 weeks of abrocitinib (100 mg daily), a JAK1 inhibitor, with sustained control at 2 months follow-up. This case adds to growing evidence that JAK inhibitors, particularly abrocitinib, may serve as an effective targeted therapy for refractory Hailey-Hailey disease. Further clinical trials are needed to confirm its long-term efficacy and safety."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Genetic Disorders • Immunology • Inflammation • Pain • IL13 • IL4

Acupoint Injection Combined with BCG-PSN and Thymosin Enteric-Coated Tablets Improve China Han Psoriasis Vulgaris by Regulating T Cell Subsets. (PubMed, Psoriasis (Auckl)) - "Multivariable Cox regression analysis demonstrated that MII significantly reduced psoriasis relapse risk versus NB-UVB (58.7% reduction; HR = 0.413, 95% CI: 0.329-0.517, P < 0.001) and acitretin (65.3% reduction; HR = 0.347, 95% CI: 0.276-0.435, P<0.001). Acupoint injection combined with BCG-PSN, thymosin enteric-coated tablets and levamisole treat psoriasis and prevent relapse of psoriasis, via modulation of Treg/Th1/Th17."

Journal • Dermatology • Immunology • Inflammation • Psoriasis • IFNG • IL17A

A Case Report of Successful Treatment of Keratoderma Secondary to Severe Plantar Psoriasiform Dermatitis with Roflumilast Cream (CDA 2025) - "His medical history included dyslipidemia, alcohol use disorder, and non-alcoholic fatty liver disease, precluding the use of systemic treatments such as Methotrexate and Acitretin due to hepatotoxicity risk...Given the refractory nature of the condition and the patient’s contraindications to systemic therapy, the patient was enrolled for Dupilumab and while awaiting approval was prescribed Roflumilast 0.3% cream off-label for once-daily application...Its favorable safety profile, tolerability, and cost-effectiveness compared to biologics suggest its potential as a viable treatment option for PSD. Further studies are warranted to evaluate Roflumilast’s efficacy in inflammatory dermatoses and role in managing refractory cases."

Case report • Clinical • Addiction (Opioid and Alcohol) • Atopic Dermatitis • Dermatitis • Dermatology • Dyslipidemia • Hepatology • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Psoriasis

Renal safety of biologic and systemic therapies for psoriasis: A systematic review (CDA 2025) - "The greatest decreases in eGFR were reported with ustekinumab (-2.1%, n=271; mean duration: 671.8 days), adalimumab (-2.1%, n=163; mean duration: 587.1 days), and golimumab (-3.0%, n=105; mean duration: 730.0 days). The greatest decreases in eGFR were reported with cyclosporine (-8.4%, n=577; mean duration: 558.1 days), acitretin (-2.0%, n=256; mean duration: 730.0 days), and methotrexate (-1.6%, n=389; mean duration: 657.9 days). Conclusions Biologic therapy in psoriasis patients exhibited 3-fold lower declines in eGFR compared to conventional systemic therapies (-1.1%/year vs -3.3%/year, p<0.0001), approximating the -1%/year eGFR decline observed in the general population beginning in the third decade of life."

Clinical • Review • Chronic Kidney Disease • Dermatology • Immunology • Inflammation • Nephrology • Psoriasis • Renal Disease

The Sinister Side of 5 Alpha Reductase Inhibitor Use: Drug-Induced Melasma (CDA 2025) - "Finasteride and dutasteride, 5-alpha reductase inhibitors (5-ARIs), are off-label treatments for androgen-related conditions in women, and on-label treatments for androgenetic alopecia and benign prostatic hypertrophy in men...Case 1 : A 53-year-old healthy woman was prescribed oral finasteride (2.5 mg daily, later increased to 5 mg) and topical minoxidil compound for frontal fibrosing alopecia (FFA)...She was prescribed acitretin as a non-immunosuppressive alternative for her FFA. Case 2 : A 66-year-old male with a history of prostate pathology presented with one year history of melasma on his forehead and temples, treated unsuccessfully with hydroquinone, tretinoin, and fluocinonide. Despite trials of cysteamine, tretinoin, and oral tranexamic acid, his melasma persisted... These cases highlight the potential for 5-ARIs to induce melasma in both men and women taking finasteride without prior melasma. Dermatologists should consider this rare side effect when assessing..."

Alopecia • Benign Prostatic Hyperplasia • Dermatology • Dermatopathology • Fibrosis • Immunology • Sexual Disorders

Oral tofacitinib for generalized Dowling-Degos disease with refractory pruritus: a case report. (PubMed, J Dermatolog Treat) - "The patient was initially treated with oral acitretin (20 mg/day) combined with prednisone (20 mg/day) for 1 month, followed by maintenance monotherapy with tofacitinib (5 mg twice daily). No adverse events occurred. Tofacitinib represents a promising therapeutic option for DDD with refractory pruritus."

Journal • Dermatology • Gastrointestinal Disorder • Pruritus

Nicotinamide for secondary keratinocyte carcinoma prevention in solid organ transplant recipients. (PubMed, Arch Dermatol Res) - "Sensitivity analyses excluding patients on concomitant acitretin confirmed that reductions in total KC incidence maintained significance at both one-year and two-year intervals. Nicotinamide supplementation significantly decreased KC incidence in immunosuppressed SOTRs over the one-year and two-year intervals. We recommend nicotinamide as a low-risk, low-cost chemopreventive supplement for reducing KCs in SOTRs."

Journal • Retrospective data • Basal Cell Carcinoma • Bowens Disease • Non-melanoma Skin Cancer • Oncology • Solid Organ Transplantation • Squamous Cell Carcinoma • Transplantation

Acitretin chemoprevention in non-melanoma skin cancer patients with chronic hematopoietic disease: findings from three independent databases. (PubMed, Br J Dermatol) - No abstract available

Journal • Genetic Disorders • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor

Not Just an Itch: A Rare Dermatological Manifestation in Chronic Kidney Disease (ERA 2025) - "Her medical history includes long-standing hypertension treated with irbesartan, a surgically and endovascularly managed cerebral aneurysm in 2006, and a history of preeclampsia and HELLP syndrome during pregnancies (G5P5)...Current medications include esomeprazole, acetylsalicylic acid, sertraline, epoetin beta, folic acid, sevelamer, cinacalcet, cholecalciferol, calcitriol, and lactulose...The onset of the lesions coincided with the initiation of atorvastatin therapy, which was discontinued without clinical improvement...Treatment was started with acitretin 10 mg, allopurinol 100 mg, and emollients, resulting in initial improvement... This case underscores the importance of recognizing RPC as a rare but clinically significant skin disorder, particularly in patients with systemic illnesses like CKD. While uncommon, its association with systemic diseases highlights the need for a multidisciplinary approach. After excluding potential drug-induced causes, a skin biopsy..."

Autosomal Dominant Polycystic Kidney Disease • Cardiovascular • Chronic Kidney Disease • Dermatology • Diabetes • Diabetic Nephropathy • Genetic Disorders • Gynecology • Hypertension • Metabolic Disorders • Mood Disorders • Nephrology • Oncology • Polycystic Kidney Disease • Pruritus • Renal Disease • Vascular Neurology

Dissecting Cellulitis of the Scalp: Treatment responses in a retrospective cohort study. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Retrospective data • Dermatology

"Full-naïve" patients: the impact of previous methotrexate, cyclosporine, and acitretin on first-line biologics response in the treatment of moderate-to-severe psoriasis - a monocentric retrospective study. (PubMed, Expert Opin Biol Ther) - "In multivariate analysis, the advantage given by acitretin was lost. Previous systemic therapy in bio-naive patients does not appear to result in a differential response to biologics during the first year of treatment."

Journal • Retrospective data • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Acitretin-Induced Paronychia and Periungual Granulation. (PubMed, J Cutan Med Surg) - No abstract available

Journal

Acrodermatitis Continua of Hallopeau - clinical review and proposed management algorithm. (PubMed, J Am Acad Dermatol) - "Acitretin is recommended as first-line treatment, though the disease often relapses, necessitating a more targeted therapeutic approach. Biologic drugs show good efficacy, but even these do not provide long-lasting remission. Despite emerging therapeutic options, ACH remains difficult to treat, and further research is needed to identify more effective strategies, including molecular profiling of the inflammatory infiltrate for a more personalized treatment."

Journal • Review • Dermatitis • Dermatology • Immunology • Inflammation • Pain • Psoriasis • Pustular Psoriasis

A Retrospective Cohort Study on Primary Cutaneous Amyloidosis (clinicaltrials.gov) - P4 | N=56 | Recruiting | Sponsor: Army Medical University, China

New P4 trial • Amyloidosis • Dermatopathology

Pityriasis rubra pilaris with symmetric polyarthralgia and lymphadenopathy (SID 2025) - "Proposed treatments include immunomodulators, acitretin, methotrexate and isotretinoin...He also had an impressive response to sonidegib, with shrinking of the large BCC tumors on his back, which were subsequently excised via Mohs...Regarding treatment of the patient's joint pain, the patient was continued on ixekizumab and started on celecoxib as needed for pain. PRP-associated arthritis is a rare component of the primarily dermatologic disorder, and it is important for clinicians to be aware of this association to adequately address joint manifestations. When applicable, paraneoplastic PRP should be explored, and underlying neoplasms should be treated."

Genetic Disorders • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Non-melanoma Skin Cancer • Pain • Rheumatology • Skin Cancer • Solid Tumor • IL17A

Effect of acitretin on Mohs surgery complexity, repair, and postsurgical outcomes in solid organ transplant patients: A TriNetX analysis from 2002 to 2022 (SID 2025) - "Pre-operative acitretin is associated with increased complexity of Mohs surgery and greater postoperative complications for the treatment of cSCC in SOT patients. Higher rates of graft failure, dehiscence, and SSI likely stem from both the increased surgical complexity for acitretin patients as well as acitretin's inhibition of angiogenesis and collagen synthesis during the proliferative phase of wound healing."

Clinical • Late-breaking abstract • Surgery • Genetic Disorders • Infectious Disease • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Organ Transplantation • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • Transplantation

XPC gene variation in an individual with generalized eruptive keratoacanthomas of grzybowski (SID 2025) - "Treatments included topical 5-fluorouracil, 5-fluorouracil + calcipotriene cream, imiquimod, triamcinolone cream, and clobetasol ointment; injected 5-fluorouracil and triamcinolone; and oral nicotinamide, acitretin, methotrexate, and cyclophosphamide. Similarly, GEKA has been linked to HPV 39 infection, and sporadic keratoacanthomas have shown positivity with multiple HPV subtypes, but this testing is not currently available at our institution. Further testing is indicated to determine the significance of these genetic findings and to explore the role of HPV in GEKA."

Clinical • Late-breaking abstract • Dermatology • Infectious Disease • Oncology • Squamous Cell Carcinoma • TGFBR1 • XPC